We are delighted to announce the incorporation of RIANA Therapeutics GmbH, a biotech startup focused on developing novel anti-cancer treatments. RIANA Therapeutics is a spinoff from Vetmeduni, devoted to discovering and developing innovative medicines. RIANA founders Richard Moriggl, Oliver Szolar, VetWidi, and Anna Orlova are very enthusiastic about committing to improving treatments for cancer patients. We are currently in the process of setting up research and development operations in Vienna and will keep you updated.
RIANA has its origins in 2018, when Anna Orlova and Richard Moriggl presented their promising research project “STAT5-inhibitors: Targeting STAT5 oligomerization in leukemia” at Vetmeduni’s VetIdeas Challenge. This was followed by a spin-off fellowship from the Austrian Research Promotion Agency (FFG), which enabled Anna Orlova to generate further data on her project.
Visit the Riana homepage here or read more about Riana here!
Congratulation from the whole lab on this amazing accomplishment!